Fludarabine plus high dose melphalan or busulphan are reduced intensity but truly myeloablative conditioning regimens

被引：0
|
作者：
Pardo Gonzalez, C. [1 ]
Gonzalez, A. [1 ]
Fernandez, R. [1 ]
Gonzalez, A. [1 ]
Palomo, P. [1 ]
Gonzalez, S. [1 ]
Arija, E. [1 ]
Martinez-Mugica, C. [1 ]
Rayon, C. [1 ]
Vallejo, C. [1 ]
机构：
[1] Hosp Univ Cent Asturias, Oviedo, Spain
来源：
BONE MARROW TRANSPLANTATION | 2013年 / 48卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S237 / S238
页数：2
相关论文
共 50 条
  • [1] Oral fludarabine is an effective and convenient alternative to intravenous fludarabine in fludarabine melphalan based reduced intensity conditioning regimens
    Y. Lwin
    J. Lindsay
    C. Reid
    K. Wong
    I. Kerridge
    C. Arthur
    K. Fay
    W. Stevenson
    M. Greenwood
    Bone Marrow Transplantation, 2020, 55 : 1638 - 1641
  • [2] Oral fludarabine is an effective and convenient alternative to intravenous fludarabine in fludarabine melphalan based reduced intensity conditioning regimens
    Lwin, Y.
    Lindsay, J.
    Reid, C.
    Wong, K.
    Kerridge, I.
    Arthur, C.
    Fay, K.
    Stevenson, W.
    Greenwood, M.
    BONE MARROW TRANSPLANTATION, 2020, 55 (08) : 1638 - 1641
  • [3] The Use of Busulphan As Compared to Melphalan in Combination with Fludarabine in the Reduced Intensity Conditioning Improves Overall Survival in Patients with Lymphoma
    Kekre, Natasha
    Marquez-Malaver, Francisco J.
    Caballero, Dolores
    Pinana, J. I.
    Esquirol, Albert
    Soiffer, Robert J.
    Cabrero, Monica
    Terol, M. J.
    Martino, Rodrigo
    Antin, Joseph H.
    Lopez Corral, L.
    Solano, Carlos
    Armand, Philippe
    Perez-Simon, Jose A.
    BLOOD, 2015, 126 (23)
  • [4] Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia
    DiMaggio, Elizabeth
    Zhou, Jun-Min
    Caddell, Ryan
    Tombleson, Rebecca
    Perkins, Janelle
    Anasetti, Claudio
    Khimani, Farhad
    Pidala, Joseph
    Nishihori, Taiga
    Perez, Lia
    Betts, Brian
    Fernandez, Hugo F.
    Mishra, Asmita
    LEUKEMIA & LYMPHOMA, 2020, 61 (07) : 1678 - 1687
  • [5] Comparative analysis of reduced toxicity conditioning regimens between fludarabine plus melphalan and fludarabine plus busulfex in adult patients with acute lymphoblastic leukemia
    Ahn, Jaehyun
    Yoon, Jae-Ho
    Kwag, Daehun
    Min, Gi June
    Park, Sung-Soo
    Park, Silvia
    Lee, Sung-Eun
    Cho, Byung-Sik
    Eom, Ki-Seong
    Kim, Yoo-Jin
    Kim, Hee-Je
    Min, Chang-Ki
    Cho, Seok-Goo
    Lee, Seok
    BONE MARROW TRANSPLANTATION, 2024, 59 (10) : 1413 - 1422
  • [6] Fludarabine Melphalan Versus Fludarabine Treosulfan As Reduced Intensity Conditioning Regimens in Allogeneic Hematopoietic Stem Cell Transplant - a Retrospective Analysis
    Chichra, Akanksha
    Nayak, Lingaraj
    Kothari, Rushabh
    Kalantri, Siddhesh Arun
    Bonda, Avinash
    Gokarn, Anant
    Punatar, Sachin
    Bagal, Bhausaheb
    Kannan, Sadhana
    Mathew, Libin J.
    Khattry, Navin
    BLOOD, 2019, 134
  • [7] Fludarabine and Melphalan Reduced Toxicity Versus a Myeloablative Fludarabine and Busulfan Conditioning Regimen for Acute Myeloid Leukemia
    Mathews, Vikram
    Kulkarni, Uday
    Selvarajan, Sushil
    Joshi, Nutan Damodar
    Fouzia
    Korula, Anu
    Lionel, Sharon Anbumalar
    Lakshmi, Kavitha M.
    Srivastava, Alok
    George, Biju
    Abraham, Aby
    BLOOD, 2023, 142
  • [8] Randomized Trial of Myeloablative Conditioning Regimens: Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine
    Lee, Je-Hwan
    Joo, Young-Don
    Kim, Hawk
    Ryoo, Hun Mo
    Kim, Min Kyoung
    Lee, Gyeong-Won
    Lee, Jung-Hee
    Lee, Won-Sik
    Park, Jae-Hoo
    Bae, Sung-Hwa
    Hyun, Myung Soo
    Kim, Dae-Young
    Kim, Sung-Doo
    Min, Young Joo
    Lee, Kyoo-Hyung
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06) : 701 - 709
  • [9] Immune Reconstitution after Alemtuzumab, Fludarabine, and Melphalan Reduced Intensity Conditioning
    Daniels, Pauline A.
    Bleesing, Jack
    Chandra, Sharat
    Dandoy, Christopher E.
    Davies, Stella M.
    El-Bietar, Javier
    Grimley, Michael S.
    Jodele, Sonata
    Jordan, Michael B.
    Khandelwal, Pooja
    Kumar, Ashish
    Mehta, Parinda A.
    Myers, Kasiani C.
    Nelson, Adam S.
    Marsh, Rebecca A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S163 - S164
  • [10] High dose idarubicine, busulphan and melphalan conditioning regimen for lymphoproliferative disorders
    Trasarti, S
    Meloni, G
    Capria, S
    Bongarzoni, V
    Ferrazza, G
    Iodice, F
    Proia, A
    Trisolini, SM
    Mandelli, F
    BONE MARROW TRANSPLANTATION, 1998, 21 : S100 - S100
12345